Alexander M A, Bennicelli J, Guerry D
Graduate Group in Immunology, University of Pennsylvania School of Medicine, Philadelphia 19104.
J Immunol. 1989 Jun 1;142(11):4070-8.
The present studies were undertaken to characterize Ag presentation by cultured human melanoma cell lines. Cell lines established from "biologically early" lesions of malignant melanoma were able to present the soluble Ag tetanus toxoid (TT) to autologous and HLA-DR-matched allogeneic, TT-immune T cell clones. Proliferation of T cell clones in response to Ag presented by primary melanoma peaked on day 2 of culture with Ag. Ag presentation was blocked by pretreatment of TT-pulsed and fixed melanoma cells with mAb against HLA-DR, but not HLA-DQ, HLA-DP, or HLA-ABC. Ag processing and presentation were inhibited by treating the melanoma cells with ammonium chloride. In parallel with previous findings from this laboratory demonstrating the inability of cell lines cultured from "advanced" primary or metastatic melanoma to induce autologous T cell proliferation, such cell lines also failed to present this exogenous Ag despite the presence of cell-surface HLA-class II molecules. Thus, in contrast to the finding in biologically early melanoma, none of the multiple TT-immune, T cell clones from autologous patients or HLA-DR matched donors was able to respond to TT presented by melanoma cells cultured from advanced disease. Co-incubation studies revealed that metastatic melanoma cells did not secrete inhibitory substances during the APC assay, however, they were able to process TT, rendering it "immunogenic" in the presence of fixed, autologous non-T cells. When fixed, autologous melanoma cells were assayed for their ability to present processed Ag; fixed cells of early but not advanced disease were able to present Ag in this setting, indicating that the presenting limb becomes flawed in the evolution of the metastatic phenotype. Finally, studies of chloroquine inhibition of the capacity of melanoma cells derived from early primary disease to stimulate autologous peripheral blood T cells suggest that such cells process and present tumor-associated Ag in the same fashion as the "model" Ag TT.
本研究旨在对培养的人黑色素瘤细胞系的抗原呈递特性进行表征。从恶性黑色素瘤“生物学早期”病变建立的细胞系能够将可溶性抗原破伤风类毒素(TT)呈递给自体及 HLA-DR 匹配的同种异体、TT 免疫的 T 细胞克隆。T 细胞克隆对原发性黑色素瘤呈递的抗原的增殖反应在与抗原共培养的第 2 天达到峰值。用抗 HLA-DR 的单克隆抗体预处理 TT 脉冲和固定的黑色素瘤细胞可阻断抗原呈递,但抗 HLA-DQ、HLA-DP 或 HLA-ABC 的单克隆抗体则不能。用氯化铵处理黑色素瘤细胞可抑制抗原加工和呈递。与本实验室先前的研究结果一致,即从“晚期”原发性或转移性黑色素瘤培养的细胞系无法诱导自体 T 细胞增殖,尽管这些细胞系存在细胞表面 HLA-II 类分子,但它们也无法呈递这种外源性抗原。因此,与生物学早期黑色素瘤的发现相反,来自自体患者或 HLA-DR 匹配供体的多个 TT 免疫的 T 细胞克隆均无法对从晚期疾病培养的黑色素瘤细胞呈递的 TT 作出反应。共孵育研究表明,转移性黑色素瘤细胞在抗原呈递细胞检测期间不分泌抑制性物质,然而,它们能够加工 TT,使其在存在固定的自体非 T 细胞的情况下具有“免疫原性”。当检测固定的自体黑色素瘤细胞呈递加工抗原的能力时;早期而非晚期疾病的固定细胞在此情况下能够呈递抗原,这表明在转移性表型的演变过程中,呈递环节出现了缺陷。最后,对氯喹抑制早期原发性疾病来源的黑色素瘤细胞刺激自体外周血 T 细胞能力的研究表明,此类细胞加工和呈递肿瘤相关抗原的方式与“模型”抗原 TT 相同。